Kim Young-Wan, Kim Nam-Kyu, Min Byung-Soh, Lee Kang-Young, Sohn Seung-Kook, Cho Chang-Hwan
From the Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
Ann Surg. 2009 Jun;249(6):965-72. doi: 10.1097/SLA.0b013e3181a6cc25.
This study was designed to determine whether the number of lymph nodes retrieved influence staging and survival in patients with stage II and III rectal cancer that undergo tumor-specific mesorectal excision.
The prognostic impact of the retrieved nodes has been emphasized in patients with colorectal cancer, but few studies have focused on patients with rectal cancer.
A total of 900 patients who underwent tumor-specific mesorectal excision with curative intent and adjuvant chemoradiation therapy for stage II and III rectal cancer from January 1989 to December 2006 were analyzed.
Cancer-specific survival (CSS) of stage II patients with less than 15 nodes (25th percentile) was not different from stage III patients, but CSS was better in stage II patients with more than 15 nodes. When using cutoff values of the 25th and 50th percentiles (22 and 31 nodes), recurrence-free survival (RFS) was statistically different among subgroups of stage II and III patients. In multivariate analysis, stage II disease with less than 15 nodes retrieved was an adverse factor for CSS and RFS. In Kaplan-Meier survival analysis, using cutoff values, the difference for CSS was not significant with 22 and more nodes and the difference for RFS was not observed with 23 and more nodes.
The number of lymph nodes retrieved is closely associated with survival and recurrence in patients with stage II rectal cancer and, for more accurate prognostic stratification, at least 22 and 23 nodes seem to be necessary, respectively, for CSS and for RFS.
本研究旨在确定在接受肿瘤特异性直肠系膜切除术的II期和III期直肠癌患者中,所获取淋巴结的数量是否会影响分期和生存情况。
所获取淋巴结的预后影响在结直肠癌患者中已得到强调,但很少有研究聚焦于直肠癌患者。
对1989年1月至2006年12月期间共900例接受肿瘤特异性直肠系膜切除术且有治愈意图并接受辅助放化疗的II期和III期直肠癌患者进行分析。
淋巴结数量少于15个(第25百分位数)的II期患者的癌症特异性生存(CSS)与III期患者无差异,但淋巴结数量超过15个的II期患者CSS更好。当使用第25和第50百分位数的临界值(22个和31个淋巴结)时,II期和III期患者亚组间的无复发生存(RFS)在统计学上存在差异。多因素分析显示,所获取淋巴结数量少于15个的II期疾病是CSS和RFS的不良因素。在Kaplan-Meier生存分析中,使用临界值时,淋巴结数量为22个及以上时CSS差异无统计学意义,淋巴结数量为23个及以上时未观察到RFS差异。
所获取淋巴结的数量与II期直肠癌患者的生存和复发密切相关,为了更准确地进行预后分层,对于CSS和RFS而言,似乎分别至少需要22个和23个淋巴结。